Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc. (AMPH)
Filing Type: Form 8-K (Current Report)
Date of Report: October 21, 2025
Reporting Period: Event-based report regarding a material definitive agreement entered into on October 21, 2025.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreement Details
On October 21, 2025, Amphastar Pharmaceuticals, Inc. entered into a Distribution Agreement with Nanjing Chengong Pharmaceutical Co., Limited ("Chengong"), a subsidiary of Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin").
- Product: BAQSIMI® (nasal powder).
- Region: Mainland China, Taiwan, Hong Kong, and Macau (Greater China).
- Role: Chengong appointed as the exclusive distributor to market and sell BAQSIMI® in the region.
- Responsibilities: Chengong is responsible for obtaining regulatory approvals and performing required post-marketing clinical trials.
- Term: 10 years from the Effective Date, with termination rights without cause available after the 4th Contract Year.
- Financial Terms:
- Chengong is subject to minimum purchase amounts per contract year.
- Profit sharing applies to earnings above a certain floor price per unit, based on Chengong's per unit net revenue.
- Total revenue for the 10-year period is not determinable at this time.
- Payments will be made in U.S. dollars.
Related Party Transaction and Governance
The agreement constitutes a related party transaction. Dr. Jack Zhang (CEO, President, Director) and Dr. Mary Luo (Chairman, COO, Director) of Amphastar, along with certain family members, beneficially own a majority of the equity interest in Hanxin (Chengong's parent company). The independent and disinterested members of the Audit Committee evaluated and approved the agreement.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes statements regarding expected performance and payments under the agreement. These are based on current expectations and are subject to risks and uncertainties.
Risks and Contingencies:
- Actual results may differ materially due to changes in laws and regulations.
- Supply chain disruptions.
- Regulatory approval requirements in the Greater China region.
- Fluctuations in per unit net revenues affecting total revenue determinability.
Investor Verification Checklist
- Verify the full text of the Distribution Agreement and appendices (safety and data exchange agreement, quality agreement) when filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2025.
- Confirm the specific minimum purchase amounts and the "floor price" mechanism for profit sharing, as these are not detailed in the 8-K.
- Monitor regulatory progress for BAQSIMI® in the Greater China region, as Chengong is responsible for approvals.
- Review the related party transaction disclosure in the 2025 Definitive Proxy Statement (Schedule 14A filed April 14, 2025) for further details on ownership interests.